Topic summary

The most common factual error about semaglutide on the internet — what changed since

Compounds › Semaglutide effect size randomised trial SELECT trial type 2 diabetes semaglutide

This is a generated summary. It shows the 7 most-liked posts from a topic of 47, in their original order, with the accepted answer included where one exists. It is a reading aid and it will miss nuance — the full topic is the record.

b.demirTL2 Moderator8 Jan 2026#4

s.bruun, post #3: Worth separating two things that the opening post runs together. Semaglutide versus liraglutide in STEP 8: semaglutide produced greater weight reduction and the discontinuation rates differed. But the trial was open-label for the dosing schedule, which admits expectation effects. Weekly versus daily itself is part of the comparison, not… Go to post

post #3 is right about the mechanism and I think understates the practical bit.

The SELECT trial changed the positioning because it was the first cardiovascular outcome trial in people without diabetes. That decoupled the cardiovascular argument from glycaemic control, which is why it mattered beyond its own numbers.

24 likes in reply to #3 7mo

BGiordanoTL2Member16 Jan 2026#8

Approved indications differ by jurisdiction and change. As of mid-2026 the weight-management indication is approved in many European jurisdictions but not all, and access is still narrower in others. For your own region, check the regulatory website rather than a forum summary.

32 likes 6mo

e.ferrariTL2 Moderator27 Jan 2026 · edited#15

Picking up post #12: that is the part I would want checked first.

The C-cell question: semaglutide triggered medullary thyroid carcinoma in rodent toxicology studies. A signal in rodents does not automatically appear in humans, but it is the reason the compound is contraindicated in people with personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2.

30 likes 6mo

ambient_reviewTL3Regular4 Feb 2026#20

23 likes 6mo

isotonic_sheetTL3Regular6 Feb 2026#21

s.achebe, post #11: This follows post #8 rather than contradicting it. The STEP programme populations were selected: enrollment criteria required baseline body mass index over 30, no recent blood pressure crisis, no recent retinopathy, no renal disease at the time. Applying results from that population to someone well outside it is an extrapolation and… Go to post

I read post #19 twice before replying, because I had assumed the opposite.

The mass figure differs between sources because of how the different entities report it. The monoisotopic mass of the bare peptide is one number; the mass including the acylation is another. Different sources emphasise different details.

32 likes in reply to #11 6mo

maintenance_modeTL3Regular11 Feb 2026#25

Coming back to post #23, because the follow-up matters more than the original answer.

Is there a ceiling dose beyond which the effect plateaus? The trials did not study that because they stopped at 2.4 mg. Some people report trying higher doses, but trial data is absent and off-label dosing enters territory this site does not advise on.

24 likes in reply to #11 5mo

j.nascimentoTL2 Moderator26 Feb 2026#36

Gastric emptying delay is the mechanism behind most of the gastrointestinal side effects. Slowing the stomach empties it feeds less food into the intestines at a time, which is part of the satiety mechanism but is also why nausea is dose-dependent and titration-dependent.

29 likes 5mo

Read the full topic (47 posts)

Suggested topics

Topic	Participants	Replies	Views	Activity
Coming back to: Semaglutide in people without diabetes: what the evidence base looks like Compounds › Semaglutide effect size randomised trial SELECT trial On the subject in the title: Semaglutide in people without diabetes: what the evidence base looks like Working notes rather than a conclusion. Session topic: STEP 2 ( Lancet , 2021). Please read it before…	+41	46	1.2k	4mo
Why semaglutide solutions can look faintly opalescent and when that matters Compounds › Semaglutide semaglutide SELECT trial randomised trial effect size Solved The question in the title: Why semaglutide solutions can look faintly opalescent and when that matters I will give what I have already checked below so nobody repeats it. Comparing LEADER ( N Engl J Med ,…	+73	79	2k	4mo
What the published dose-response for semaglutide actually looks like above 2.4 mg Compounds › Semaglutide STEP programme type 2 diabetes effect size SELECT trial Solved What the published dose-response for semaglutide actually looks like above 2.4 mg — that is the question, and I have not found it answered plainly anywhere I have looked. Session topic: SURMOUNT-4 ( JAMA ,…		2	10k	3mo
Comparing the STEP programme populations: who was actually enrolled Compounds › Semaglutide SELECT trial STEP programme semaglutide effect size Solved Comparing the STEP programme populations: who was actually enrolled Writing it up because I had to work it out twice and would rather nobody else did. Comparing STEP 1 ( N Engl J Med , 2021) with FLOW ( N…		2	7.5k	2mo
What SELECT changed about how semaglutide is discussed, and what it did not Compounds › Semaglutide STEP programme type 2 diabetes randomised trial Solved Asking directly, because I could not find a straight answer: What SELECT changed about how semaglutide is discussed, and what it did not Session topic: SURMOUNT-1 ( N Engl J Med , 2022). Please read it before…	+120	132	2k	14mo

Related topics — sharing the tags effect size, randomised trial, SELECT trial

Topic	Participants	Replies	Views	Activity
Food effects on oral incretin absorption: what is documented Compounds › Oral incretins PIONEER programme SOUL trial randomised trial oral semaglutide Solved Under review On the subject in the title: Food effects on oral incretin absorption: what is documented Working notes rather than a conclusion. Session topic: SURMOUNT-1 ( N Engl J Med , 2022). Please read it before…		2	4.4k	12mo
A 40-week log with the measurement method stated — does this still hold? Outcomes › Progress reports effect size DXA data table Solved A 40-week log with the measurement method stated — does this still hold? I have a specific reason for asking rather than idle curiosity, and the context is below. Longitudinal report with the method stated,…	+1	5	14k	2mo
Comparing the STEP programme populations: who was actually enrolled — the long version Compounds › Semaglutide STEP programme randomised trial type 2 diabetes On the subject in the title: Comparing the STEP programme populations: who was actually enrolled — the long version Working notes rather than a conclusion. Comparing PIONEER 6 ( N Engl J Med , 2019) with…		4	7.7k	11mo
A 40-week log with the measurement method stated — what changed since Outcomes › Progress reports effect size data table DXA long read Solved A 40-week log with the measurement method stated — what changed since Writing it up because I had to work it out twice and would rather nobody else did. Longitudinal report with the method stated, because a…	+9	13	2.1k	9h
Glucagon receptor agonism in a weight-loss compound Pharmacology › Receptor biology semaglutide retatrutide tirzepatide Pinned On the subject in the title: Glucagon receptor agonism in a weight-loss compound Working notes rather than a conclusion. Posting the method first, because I know what the first three replies will otherwise…		2	5.1k	20mo